2026年欧洲肿瘤内科学会亚洲年会（ESMO Asia 2026）将于2026年12月4日至6日于新加坡举办，汇聚全球顶尖专家，分享前沿科研成果与临床实践智慧。目前会议入选研究标题已正式公布，其中头颈肿瘤领域（不含甲状腺癌）共有30项中国研究入选，涵盖8项口头报告及22项壁报，《肿瘤瞭望》特将研究信息整理如下，以供参考，如有疏漏，敬请留言指正。
编者按：2026年欧洲肿瘤内科学会亚洲年会（ESMO Asia 2026）将于2026年12月4日至6日于新加坡举办，汇聚全球顶尖专家，分享前沿科研成果与临床实践智慧。目前会议入选研究标题已正式公布，其中头颈肿瘤领域（不含甲状腺癌）共有30项中国研究入选，涵盖8项口头报告及22项壁报，《肿瘤瞭望》特将研究信息整理如下，以供参考，如有疏漏，敬请留言指正。
Proffered Paper（优选口头报告）
日期：2026年12月5日
时间：16:15 - 17:45
地点：Hall 401
550O - Cetuximab Combined With Tislelizumab and Chemotherapy in the Treatment of Unresectable Locally Advanced Head and Neck Squamous Cell Carcinoma: A Prospective, Single-Arm, Phase II Study
西妥昔单抗联合替雷利珠单抗及化疗治疗不可切除局部晚期头颈部鳞状细胞癌：一项前瞻性、单臂、II期研究
报告时间：16:15 - 16:25
讲者：李娟 (陆军军医大学陆军特色医学中心)
551O - Amivantamab (ami) in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) after immune checkpoint inhibitor and chemotherapy: Asian subgroup analysis from the phase 1b/2 OrigAMI-4 study
埃万妥单抗治疗免疫检查点抑制剂和化疗经治后复发/转移性头颈部鳞状细胞癌（HNSCC）：1b/2期OrigAMI-4研究的亚洲亚组分析
报告时间：16:25 - 16:35
讲者：楊慕華 (Muh-Hwa Yang) (中国 台北荣民总医院)
553O - Zongertinib in Pretreated HER2-Positive Salivary Gland Cancer
宗格替尼治疗经治的HER2阳性唾液腺癌
报告时间：17:07 - 17:17
讲者：郭晔 同济大学附属东方医院
554O - Diagnostic Refinement in Challenging Head and Neck Cancers: A Pan-Asian Multi-Institutional Collaboration (MASTER KEY Asia)
疑难头颈癌的诊断精进：泛亚洲多机构合作研究（MASTER KEY Asia）
报告时间：17:17 - 17:27
讲者：Huiching Wang (中国 高雄医学大学附设医院)
Rapid Oral（快速口头报告）
日期：2026年12月5日
时间：09:30 - 10:30
地点：Hall 402
555RO - A single-arm, multicenter, prospective Phase II study of tislelizumab in combination with nimotuzumab and GP induction followed by IMRT and tislelizumab plus nimotuzumab for high-risk locally advanced nasopharyngeal carcinoma: primary endpoint analysis
替雷利珠单抗联合尼妥珠单抗与GP方案诱导化疗后行IMRT，并继续替雷利珠单抗联合尼妥珠单抗治疗高危局部晚期鼻咽癌的单臂、多中心、前瞻性II期研究：主要终点分析
报告时间：09:30 - 09:35
讲者：邱素芳 (福建省肿瘤医院)
556RO - Efficacy of Immediate Radiotherapy Versus Salvage Radiotherapy in De Novo Metastatic Nasopharyngeal Carcinoma Patients Responsive to Chemoimmunotherapy
即刻放疗对比挽救性放疗在化疗免疫治疗应答的初诊转移性鼻咽癌患者中的疗效
报告时间：09:35 - 09:40
讲者：张绮彤 (中山大学肿瘤防治中心)
558RO - Efficacy and Safety Results of Pulsed Radiotherapy combined with Tislelizumab in patients with recurrent head and neck squamous cell carcinoma
脉冲放疗联合替雷利珠单抗治疗复发头颈部鳞状细胞癌的疗效与安全性结果
报告时间：10:00 - 10:05
讲者：张希梅 (天津医科大学肿瘤医院)
559RO - Exosomal PD-L1/PD-L2 as Predictive Biomarkers for First-Line Pembrolizumab plus Nab-Paclitaxel and Platinum in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
外泌体PD-L1/PD-L2作为帕博利珠单抗联合白蛋白紫杉醇和铂类一线治疗复发/转移性头颈部鳞状细胞癌的预测性生物标志物
报告时间：10:05 - 10:10
讲者：高茹云 (中国医学科学院肿瘤医院)
Poster&ePoster（壁报及电子壁报）
560P - Pembrolizumab Plus Nab-paclitaxel and Platinum as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: 3-Year Follow-Up Results from a Phase II Prospective Study
帕博利珠单抗联合白蛋白紫杉醇和铂类作为复发/转移性头颈部鳞状细胞癌一线治疗方案：一项II期前瞻性研究的3年随访结果
讲者：Le Tang (Beijing, CN)
561P - Survival and Biomarker Analysis of Neoadjuvant Camrelizumab Plus Chemotherapy in Locally Advanced Stage Hypopharyngeal Carcinoma: Phase II trial
卡瑞利珠单抗联合化疗新辅助治疗局部晚期下咽癌的生存及生物标志物分析：II期研究
讲者：Xiaohui Yuan (Shanghai, CN)
565P - A National Cohort Study of Standardized Hybrid Microlaryngoscopy Training: Improved Oncologic Competence and Surgical Safety for Laryngeal Lesions
标准化杂交显微喉镜训练全国队列研究：喉部病变肿瘤学能力与手术安全性的提升
讲者：Kai Sun (Guangzhou, CN)
566P - Neoadjuvant Cetuximab β Plus Tislelizumab and Chemotherapy for Locally Advanced Nasopharyngeal Carcinoma: A Prospective, Single-Arm, Phase II Clinical Study
西妥昔单抗β联合替雷利珠单抗及化疗新辅助治疗局部晚期鼻咽癌：一项前瞻性、单臂、II期临床研究
讲者：Guoyi Zhang (Foshan, CN)
568P - Head-to-Head Comparison of Multi-Cancer Early Detection (MCED), EBV Serology, and Plasma EBV DNA for Nasopharyngeal Carcinoma (NPC) Detection
多癌种早期检测（MCED）、EBV血清学与血浆EBV DNA检测鼻咽癌的头对头比较
讲者：Yihui Wen (Guangzhou, CN)
569P - Performance of a methylation-based multi-cancer early detection (MCED) test in pharyngeal cancers
基于甲基化的多癌种早期检测（MCED）检测在咽癌中的效果
讲者：Yihui Wen (Guangzhou, CN)
570P - Cell-Free DNA Methylation Liquid Biopsy for Multi-Cancer Early Detection (MCED): A Tool for Screening and Differential Diagnosis of Nasopharyngeal Malignancies
用于多癌种早期检测（MCED）的cfDNA甲基化液体活检：鼻咽恶性肿瘤筛查与鉴别诊断工具
讲者：Shenhong Qu (Nanning, CN)
578P - Real-World Outcomes and Predictors of Durable Progression-Free Survival with Immune Checkpoint Inhibitors in Upper Aerodigestive Tract Squamous Cell Carcinoma
上呼吸消化道鳞状细胞癌免疫检查点抑制剂治疗的真实世界结局及持久无进展生存的预测因素
讲者：Chia-Ying Wu (Taipei City, CN)
589P - Risk-Stratified Management of Stage IB Nasopharyngeal Carcinoma Under the 9th Edition TNM Staging System: A Prognostic Nomogram Integrating MRI Nodal Features and EBV DNA
第9版TNM分期系统下IB期鼻咽癌的风险分层管理：整合MRI淋巴结特征和EBV DNA的预后列线图
讲者：Jiali Huang (Fuzhou, CN)
590P - Post-immunochemotherapy PET/CT-guided risk stratification identifies candidates for metastasis-directed therapy in de novo metastatic nasopharyngeal carcinoma
免疫联合化疗后PET/CT引导的风险分层以识别初诊转移性鼻咽癌中适合转移灶精准治疗的患者
讲者：Wanping Guo (Guangzhou, CN)
591P - Metastatic Sites Inform Treatment Prioritization and Survival Benefit After First-Line Chemotherapy in De Novo Metastatic Nasopharyngeal Carcinoma
转移部位对初诊转移性鼻咽癌一线化疗后治疗优先级和生存获益的指导作用
讲者：Qin Liu (Guangzhou, CN)
593P - Patterns and predictors of immune-related adverse events in nasopharyngeal carcinoma treated with immune checkpoint inhibitors: an integrated FAERS and clinical cohort analysis
免疫检查点抑制剂治疗鼻咽癌中免疫相关不良事件的特征与预测因素：FAERS与临床队列的综合分析
讲者：Qi Yang (Guangzhou, CN)
594P - Topical Five Paced Viper Fat Extract Prevents Radiation Dermatitis in Nasopharyngeal Carcinoma Patients Undergoing IMRT
局部外用五步蛇蛇脂提取物预防鼻咽癌调强放疗相关放射性皮炎的作用
讲者：Chao Li (Sanming City, CN)
598P - Circulating CD47-Enriched Microvesicles as a Non-Invasive Liquid Biopsy Biomarker for Dynamic Prediction of Anti-PD-1 Resistance and Immune Suppression in Head and Neck Squamous Cell Carcinoma.
循环CD47富集微囊泡作为无创液体活检生物标志物动态预测头颈部鳞状细胞癌抗PD-1耐药和免疫抑制作用
讲者：Nini Li (Zhuhai, CN)
601P - A ceRNA-mediated PRKCB axis drives immune remodeling and tertiary lymphoid structure formation following antiangiogenic immunotherapy in nasopharyngeal carcinoma
ceRNA介导的PRKCB轴在鼻咽癌抗血管生成免疫治疗后驱动免疫重塑和三级淋巴结构形成
讲者：Shuhui Dong (Guangzhou, CN)
602P - Progressive Role of POSTN⁺ Fibroblasts in Driving Tumor-Stroma Crosstalk and Malignant Progression in Laryngeal Squamous Cell Carcinoma
POSTN+成纤维细胞在驱动喉鳞状细胞癌肿瘤-基质串扰和恶性进展中的进行性作用
讲者：Zhimou Cai (Guangzhou, CN)
603P - Plasma extracellular vesicle-associated LINC02420 identifies aggressive head and neck cancer and mediates AEG-1–p65–p300/HIF1A-dependent glycolytic regulation
血浆细胞外囊泡相关LINC02420识别侵袭性头颈癌并介导AEG-1-p65-p300/HIF1A依赖性糖酵解调控
讲者：Yun Li (Guangzhou, CN)
604P - Real-time AI quality control and lesion-risk stratification during nasopharyngolaryngoscopy
鼻咽喉镜检查中实时AI质量控制与病变风险分层
讲者：Yuan Y. Li (Guangzhou, CN)
605P - A CT-based Deep Learning Model for Non-invasive Preoperative T-staging of Glottic Laryngeal Carcinoma: A Multicenter Study with Prospective Validation
基于CT的深度学习模型用于声门型喉癌术前无创T分期：一项前瞻性验证的多中心研究
讲者：Yi Shuai (Guangzhou, CN)
611P - Diagnosis of lymph node metastasis in oral squamous cell carcinoma by an MRI-based deep learning model
基于MRI的深度学习模型诊断口腔鳞状细胞癌淋巴结转移
讲者：Le Yang (Guangzhou, CN)
617eP - Neoadjuvant Finotonlimab Plus Chemotherapy in Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma: Preliminary Efficacy, Safety, and PET/CT Metabolic Response Results
菲诺利单抗联合化疗新辅助治疗可切除局部晚期头颈部鳞状细胞癌：初步疗效、安全性及PET/CT代谢反应结果
讲者：Wenchao Zhang (Beijing, CN)
636eP - ZC3H13-mediated m6A stabilization of CCND1 promotes malignant progression and is associated with poor anti-PD-1 response in HNSCC
ZC3H13介导的CCND1 m6A修饰稳定化促进头颈部鳞状细胞癌恶性进展及其与抗PD-1疗效不佳相关的分析
讲者：Wenqing Chen (Guangzhou, CN)